missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ ABT 263

Click to view available options
Quantity:
10 mg
50 mg
Unit Size:
10mg
50mg
Description
ABT 263 is a high affinity inhibitor of Bcl-2 family proteins (Ki values are 0.5 nM, <1 nM and <1 nM in Bcl-xL, Bcl-2 and Bcl-W respectively). ABT 263 induces G1/G0 phase arrest, apoptosis and autophagy in cancer cells in vitro (IC50 = 3.4 - 12 μM). In vivo, ABT 263 displays a synergistic antitumor effect with rituximab and Bortezomib (Cat. No. 7282), Docetaxel (Cat. No. 4056) and Erlotinib (Cat. No. 7194), and inhibits growth of SCLC xenografts when combined with (+)-JQ1 (Cat. No. 4499). ABT 263 also reduces inflammation and viral-induced senescence in SARS-CoV-2 infection in vivo, and clears senescent cells and rejuvenates aging stem cells. Orally bioavailable.
Specifications
Specifications
| Chemical Name or Material | 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1 R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide |
| CAS | 923564-51-6 |
| Quantity | 10 mg |
| Target | Bcl-2 Family Inhibitors |
| Molecular Formula | C47H55ClF3N5O6S3 |
| Purity | 0.98 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction